Related Experiment Video
Updated: Feb 13, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Genomic Testing in Lung Cancer: Past, Present, and Future
Céline Mascaux1,1, Ming-Sound Tsao1, Fred R Hirsch1
1From Assistance Publique Hôpitaux de Marseille, Mutidisicplinary Oncology and Therapeutic Innovations Department, Marseille, France; Centre de Recherche en Cancérologie de Marseille (Cancer Research Center of Marseille), Inserm UMR1068, CNRS UMR7258, and Aix-Marseille University UM105, Marseille France; Department of Pathology, University Health Network and Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada; and University of Colorado Cancer Center, Denver, Colorado.
Genomic testing identifies cancer vulnerabilities for targeted therapies, improving outcomes in advanced non-small cell lung cancer. This precision medicine approach guides treatment selection and reduces toxicity.
Area of Science:
- Oncology
- Genomics
- Translational Medicine
Background:
- Precision medicine uses tumor biomarkers to guide cancer treatment selection.
- Genomic testing identifies specific abnormalities for targeted therapies, enhancing treatment efficacy.
- This approach is crucial for advanced non-small cell lung cancer management.
Purpose of the Study:
- To review the evolution of genomic testing in lung cancer.
- To discuss current applications and future directions in lung cancer genomic profiling.
- To highlight the impact of precision medicine on patient outcomes.
Main Methods:
- Review of historical development of genomic testing in lung cancer.
- Analysis of current clinical utility of genomic biomarkers.
- Discussion of emerging trends and challenges in genomic profiling.
Main Results:
- Genomic testing has evolved significantly, with initial successes and failures shaping current practices.
- It enables personalized treatment selection, improving outcomes and reducing toxicity in lung cancer.
- Ongoing research identifies new targetable abnormalities and emphasizes longitudinal genomic profiling.
Conclusions:
- Genomic testing is integral to precision medicine in advanced non-small cell lung cancer.
- Future directions include expanding the scope of targetable mutations and addressing tumor heterogeneity.
- Continuous monitoring of genomic profiles is essential for adapting treatment strategies over time.
Related Concept Videos
Genomics
Lung Capacity
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Genome Size and the Evolution of New Genes
Comparing Mitochondrial, Chloroplast, and Prokaryotic Genomes
Pleura of the Lungs

